A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging In Patients Advanced Breast Cancer

The purpose of this study is to see whether 18F-FDHT PET/MRI scans are an effective way of identifying AR-positive breast cancer.

Inclusion Criteria:

• Age ≥ 18 years

• ECOG performance score of 0-2

• Signed informed consent

• Histologically confirmed AR+ breast cancer

  • All participants under consideration for enrollment will have their tumor specimen tested centrally at MSK; nuclear AR staining ≥ 1% will be considered positive.

• Progressive metastatic breast cancer manifested as increase in evaluable disease OR the appearance of new sites of disease since the date of the last imaging study performed and under consideration for AR-targeted therapy

• Planning to undergo treatment with agents targeting the antiandrogen signaling pathway on a clinical trial

Exclusion Criteria:

• Life expectancy < 3 months

• Pregnancy or lactation

• Participants who cannot undergo scanning because of

  • weight limits
  • devices or implants that are not MRI safe
  • allergies to contrast materials

• CNS only disease on recent imaging